Frontlight ResearchEarly access
Taking peoplePhase 4
Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis
Key facts
- Who runs it
- Erasmus Medical Center
- Where
- Netherlands18 sites in 1 countryChoose a country to see its sites
- Trial code
- NCT06766461
- EU 2024-512950-13-00
- U1111-1308-9223
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 980 people, planned
- Started
- 3 Jan 2025
- Expected to end
- 1 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Double dosing of beta-lactam antibiotic
- Record updated
- 9 January 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- ≥18 years of age
- Receiving intravenous antibiotic therapy of the target drugs (including continuous infusion of beta-lactam antibiotics)
- Primary infection
- Admitted to the ICU
- Meeting the Sepsis-3 criteria for septic shock: sepsis in addition to shock requiring the start of vasopressors to maintain a mean arterial pressure 65 mmHg or greater, and a serum lac tate level greater than 2.0 mmol/L following "adequate fluid resuscitation"
Who cannot take part
- Patients receiving target antibiotics only as prophylaxis within the context of Selective Diges tive tract Decontamination (SDD)
- Patient received the study antibiotic for more than 24 hours before inclusion
- Patient receiving extracorporeal membrane oxygenation (ECMO)
- Patient is already treated with a double dose of antibiotics based on suspected infection
- Patient or legal representative not available to give informed consent within 72 hours after admittance
- Pregnancy
- Admittance for burn wounds
- Enrolment in another interventional trial
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study is to investigate if an initial short double dose of beta-lactam antibiotics will reduce mortality in critically ill patients with sepsis.
The 2 groups in the trial
- ControlNo study treatment, for comparison
This arm will receive standard of care according to local protocol.
- InterventionTreatment being tested
This arm will be treated with double dosages of beta-lactam antibiotics the first 48 hours after inclusion.
Treatment: Double dosing of beta-lactam antibiotic
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Publications
- Record updated
- 9 January 2025